Page last updated: 2024-10-25

deferoxamine and Bone Cancer

deferoxamine has been researched along with Bone Cancer in 1 studies

Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
González Suárez, I1
Fernández Martín, JL1
Naves Díaz, M1
Cannata Andía, JB1

Other Studies

1 other study available for deferoxamine and Bone Cancer

ArticleYear
[Effect of desferrioxamine and deferiprone on osteocalcin secretion in osteoblast-type cells].
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2003, Volume: 23 Suppl 2

    Topics: Aluminum; Animals; Bone Neoplasms; Calcitriol; Cattle; Chelating Agents; Culture Media; Deferiprone;

2003